Clinical Trial Update: Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial comparing aripiprazole with standard of care on non-HDL cholesterol in adults with schizophrenia or bipolar I disorder and metabolic syndrome was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Metabolic Syndrome
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: TERMINATED | Results posted: 2011-07-21